(Q44763087)

English

Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics

scientific article published in April 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Alexander Eggermont

5

object named as

Alexander M M Eggermont

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

author name string

Peter Brouckaert

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Nozomi Takahashi

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sandra T van Tiel

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Jeroen Hostens

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Ann L B Seynhaeve

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Walter Fiers

7

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Timo L M ten Hagen

8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

language of work or name

0 references

publication date

1 April 2004

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

109

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

442-448

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

Tumor necrosis factor as an antineoplastic agent: pitfalls and promises

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

Bioavailability of recombinant tumor necrosis factor determines its lethality in mice.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

Long-circulating (sterically stabilized) liposomes for targeted drug delivery

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11703

21 January 2018

Identifiers

10.1002/IJC.11703

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44763087&oldid=2143617421"